Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paliperidone + sertraline
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy of paliperidone (an atypical antipsychotic) and sertraline (a selective serotonin reuptake inhibitor). This combination has been studied for treating schizophrenia, showing effectiveness in improving serum neuregulin levels and alleviating negative emotional effects. The mechanism involves paliperidone's antagonism of dopamine D2 and serotonin 5HT2A receptors combined with sertraline's serotonin reuptake inhibition.
02
Targets
ADRA1A (α1A)ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on paliperidone + sertraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paliperidone + sertraline.